Tech Company Financing Transactions
ReVision Therapeutics Funding Round
ReVision Therapeutics closed a $500 thousand financing round on 12/20/2011. Backers included private investors.
Transaction Overview
Company Name
Announced On
12/20/2011
Transaction Type
Venture Equity
Amount
$500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
5626 Oberlin Drive 100
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
ReVision Therapeutics is focused on developing fenretinide for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in the elderly.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Lichter
Chief Scientific Officer
Nathan Mata
Browse more venture capital transactions:
Prev: 12/20/2011: Houzz venture capital transaction
Next: 12/20/2011: Cardeas Pharma venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs